In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alfasigma S.p.A.

http://www.alfasigma.com/en

Latest From Alfasigma S.p.A.

Travere Looks Ahead To Phase III In Homocystinuria

The latest data from a Phase I/II study shows that pegtibatinase can yield a rapid, sustained reduction in homocysteine, the protein behind the underlying cause of the rare disease.

Clinical Trials Rare Diseases

Sparsentan Fails In Phase III FSGS Study, But Travere Assessing Path To Approval

Travere’s drug, approved as Filspari for immunoglobulin A nephropathy, missed its eGFR primary endpoints in focal segmental glomerulosclerosis but showed meaningful improvement in proteinuria.

Clinical Trials Rare Diseases

Calliditas Eyes Full Approval For Tarpeyo In IgAN After Positive Pivotal Update

Data from part B of the Swedish firm’s pivotal trial of Tarpeyo in the rare kidney disorder showed that the treatment effects lasted two years across the entire population, enabling the move from conditional to full approvals in several markets.

Clinical Trials Renal

Finance Watch: Summit Raises $500m For Shift From Anti-Infectives To Oncology

Public Company Edition: Summit initiated the big rights offering earlier this year as promised in December when it licensed Akeso’s PD-1/VEGF bispecific. Also, Teva sold $2.49bn in sustainability-linked notes to pay down debt, while MorphoSys, Novavax and others restructured and cut jobs.

Finance Watch Restructuring
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • ALFASIGMA
    • Defiante Farmaceutica S.A.
    • Sigma-Tau Pharma Ltd
    • Sigma-Tau Arzneimittel GmbH
    • Sigma-Tau Research Switzerland SA
    • Biofutura Pharma S.p.A.
    • Alfa Wassermann SpA
UsernamePublicRestriction

Register